| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 7.66M | — |
| Operating expense | — | — |
| Net income | -106.63M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, 38I.F returned +28.1% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +52.6% |
| 1 year | +28.1% |
| 5 years | -91.4% |
| 10 years | -36.0% |
| All-time high | €158.00 (Jun 2021) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in 38I.F would be worth today ›No. Intellia Therapeutics, Inc. has not paid a dividend in the past 12 months.
Intellia Therapeutics, Inc. is part of the Healthcare sector.
Intellia Therapeutics, Inc. has a market cap of 1.59B EUR, based on the latest quote.
Intellia Therapeutics, Inc. is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
